Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Purpose

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Condition

  • Plasma Cell Disorders

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), amyloid light chain (AL) amyloidosis or healthy controls from their households

Exclusion Criteria

  • Age under 18 years - Pregnancy - Substance abuse - Antibiotics use or gastrointestinal endoscopy in the 3 months prior to the study participation - Chronic gastrointestinal disorder - Gastrointestinal surgeries in the past 2 years - Chemotherapy (including anti-plasma cell treatment and steroids) or radiation treatment for cancer within the last 2 years or active cancer (other than plasma cell disorder)

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
MULTIPLE MYELOMA at diagnosis GROUP Multiple myeloma (before starting chemotherapy, radiation or stem cell transplant
  • Other: Non-interventional study (observational)
    Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
    Other names:
    • GMB
Amyloid at diagnosis GROUP AL amyloidosis (before starting chemotherapy or stem cell transplant)
  • Other: Non-interventional study (observational)
    Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
    Other names:
    • GMB
Poems at diagnosis GROUP POEMS at diagnosis (before starting chemotherapy, radiation, or stem cell transplant
  • Other: Non-interventional study (observational)
    Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
    Other names:
    • GMB
Poems in Remission GROUP POEMS in remission (no chemotherapy, radiation, or stem cell transplant for 2 years
  • Other: Non-interventional study (observational)
    Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
    Other names:
    • GMB
MGUS GROUP MGUS -not treated newly diagnosed
  • Other: Non-interventional study (observational)
    Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
    Other names:
    • GMB
Health controls in same household GROUP household member to be a healthy control (no chemotherapy or gastrointestinal illness to participate)
  • Other: Non-interventional study (observational)
    Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
    Other names:
    • GMB

Recruiting Locations

Mayo Clinic in Rochester
Rochester 5043473, Minnesota 5037779 55905
Contact:
Laura Hawkins
507-538-1308
hawkins.laura@mayo.edu

More Details

NCT ID
NCT06252948
Status
Recruiting
Sponsor
Mayo Clinic

Study Contact

Laura Hawkins
507-538-1308
hawkins.laura@mayo.edu

Detailed Description

The characteristics and role of gut microbiome rare plasma cell disorders- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) and amyloid light-chain (AL) amyloidosis, have not been explored; and their pathophysiology is quite elusive. To help understand rare plasma cell disorders and its association with gut microbiome, the investigators will study the stool samples of newly diagnosed POEMS patients and AL amyloidosis and compare it with patients with newly diagnosed monoclonal gammopathy of undetermined significance and multiple myeloma as well as healthy controls. Moreover, gut microbiome in newly diagnosed POEMS patients will be compared to POEMS patients in remission. It is the overall hypothesis that in POEMS patients the gut microbiome signature will differ between active disease (at diagnosis) and inactive disease (in remission), and the gut microbiome in POEMS patients will be different from patients with other plasma cell disorders and healthy controls.